BC Partners takes majority stake in IGS GeboJagema

Led by the international investment firm BC Partners alongside reinvesting consortium members Smile Invest and the executive management team, this definitive transaction secures a controlling majority stake in the Dutch tooling specialist IGS GeboJagema. Formally announced on June 9, 2025, the cross-border leveraged buyout reconfigures the target's existing shareholding structure to fuel its next phase of global expansion. Under the negotiated terms of the capital restructuring, the historical financial partner Smile Invest—which has backed the manufacturer over the past several years—will roll over a portion of its equity to retain a minority shareholding position. Conversely, the secondary financial shareholder, Rabo Private Equity, will completely liquidate its minority position and fully exit the business upon closing. The strategic rationale articulated by the acquiring private equity sponsor, steered locally by Managing Director Matthew Evans, centers on deploying institutional capital to accelerate the target's capacity to serve rapidly growing end markets. Specifically, the new ownership consortium aims to aggressively expand the manufacturer's presence within the high-demand GLP-1 segment and fund entry into adjacent healthcare verticals requiring high-precision molds. The integration roadmap heavily emphasizes continued organic expansion coupled with a targeted buy-and-build acquisition strategy designed to consolidate the fragmented healthcare toolmaking sector. For the target company, partnering with a transatlantic sponsor provides the operational scale and specialized pharmaceutical automation expertise necessary to elevate its commercial profile globally. To navigate the competitive transaction dynamics, the buy-side executive board mandated Lincoln International as its exclusive mergers and acquisitions advisor, with the advisory team led by Managing Director Sibert Meulenbelt contributing deep sector knowledge in the mold-making space. On the sell-side, the exiting and reinvesting shareholders, represented by Smile Invest Managing Partner Bart Cauberghe and Partner Ad Notenboom, engaged the investment bank Rothschild & Co to execute the comprehensive financial auction. The completion of this strategic capital transition remains strictly subject to the receipt of customary regulatory approvals and mandatory feedback from the competent workers council.